Effect of Sarcopenia on HCC After Lenvatinib and Anti-PD-1 Treatment

Wenzhou Medical University

Status: Invitation-only

Conditions: Sarcopenia; Liver Cancer

Treatments: Diagnostic Test: gait speed; ct scan; grip strength and chair stand test

Study type: Observational

Funder types: Other

Identifiers

NCT05443230

sarcopenia and prognosis

Details and patient eligibility

About

Sarcopenia is associated with the prognosis of HCC and cholangiocarcinoma. But there has been rare study focusing on the effect of sarcopenia on the prognosis of HCC treated with lenvatinib and anti-PD1.

Full description

By tracking the short-term and long-term results of HCC patients treated with lenvatinib and anti-PD1,the difference of short-term results between patients with sarcopenia and patients without sarcopenia was analyzed, and the correlation between sarcopenia and short-term and long-term results of patients after systemic treatment was explored, so as to improve people's awareness of sarcopenia and pay attention to its prevention and treatment.All implementation details are based on the newest EWGSOP definition. The investigators consecutively admitted patients the questionnaire and evaluated the assessment of muscle strength (grip strength test and chair stand test), muscle quantity (L3 plane total skeletal muscle area) and physical performance (gait test) following the F-A-C-S approach, to confirm patients with sarcopenia accurately. And by tracking the short-term and long-term outcomes, the differences were analyzed and the relationship between sarcopenia and prognosis of systemic treatment was explored.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with clinical diagnosis of liver cancer

• No cancer other than liver cancer has been diagnosed
• Age ≥18 years

Exclusion criteria

• Patients who could not complete the standard tests and questionnaires
• Patients received other therapies
• Patients who had other causes of muscle weakness (injury, fracture, stroke, etc.)
• Patients who missing CT data or CT scan did not reach the level of the third lumbar vertebra (L3)

Trial design

200 participants in 2 patient groups

patients with sarcopenia

Treatment:

Diagnostic Test: gait speed; ct scan; grip strength and chair stand test

patients without sarcopenia

Treatment:

Diagnostic Test: gait speed; ct scan; grip strength and chair stand test